Previous 10 | Next 10 |
-Expands Clinical-stage Pipeline, Further Positioning Cerecor as a Leader in Rare and Orphan Diseases -Enhances Leadership Team with the Addition of Chief Executive Officer and Chief Medical Officer -Strategic Alternatives Being Explored for Neurological Assets and Millipred ...
Cerecor (NASDAQ: CERC ): Q3 GAAP EPS of -$0.07 beats by $0.06 . Revenue of $5.61M (+37.5% Y/Y) beats by $0.58M . Press Release More news on: Cerecor Inc., Earnings news and commentary, Healthcare stocks news, ,
Sale of Pediatric Portfolio in a Deal Valued in Excess of $43 Million First Patient Enrolled in Diabetic OH Trial with CERC-301 Completed Phase 1 Healthy Volunteer Study with CERC-802 CERC-802 IND Accepted by FDA and Received Fast Track Designation ROCKVILLE, Md., Nov. 14, 2019 (GLOB...
- CERC-301 Enrolls First Patient in Diabetic Orthostatic Hypotension Trial -CERC-802 Completes Phase I Safety Study in Healthy Volunteers ROCKVILLE, Md., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in dev...
ROCKVILLE, Md., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan diseases and neurology, announced today that it has closed the sale of its pediatric portfoli...
Aytu BioScience (NASDAQ: AYTU ) has signed an asset purchase agreement to acquire a portfolio of prescription products from Cerecor (NASDAQ: CERC ) (the "Commercial Portfolio"). More news on: Aytu BioScience, Inc., Cerecor Inc., Healthcare stocks news, Read more ...
-Deal Valued in Excess of $32 Million -Eliminates Debt Associated with Avadel / Deerfield Agreement -Provides Non-Dilutive Cash Generation to Fund R&D -Extends Runway Towards NDA Submission of CERC-801 ROCKVILLE, Md., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Cerecor In...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
Mitsubishi Tanabe Pharma America ( OTCPK:MTZPY -1.5% ) initiates a Phase 3 clinical trial, BouNDless , evaluating continuous subcutaneously administered carbidopa/levodopa (ND0612) compared to the oral formulation in Parkinson's disease (PD) patients. More news on: Mitsubishi Tanabe P...
The FDA grants Fast Track status for Cerecor's (NASDAQ: CERC ) CERC-802 for the treatment of a rare inherited inborn error of metabolism called Mannose-Phosphate Isomerase Deficiency (MPI-CDG). More news on: Cerecor Inc., Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Cerecor Inc. Company Name:
CERC Stock Symbol:
NASDAQ Market:
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. “We are thrilled to have Mittie join and grow our leadership team at an exciting...
Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and safety of AVTX-009 in patients with hidradenitis suppurativa WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Ava...
WAYNE, Pa. and ROCKVILLE, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present on the Novel Immunological Mechanisms for Dermatological Disorders Panel being held at...